PACAP38´s (Pituitary Adenylate Cyclase-Activating Polypeptide) Headache Inducing Characteristics and Effects on the Cerebral Blood Flow

Danish Headache Center12 enrolled

Overview

To investigate headache score and accompanying symptoms during and after infusion of PACAP38 i migraine patients

To investigate headache score and accompanying symptoms during and after infusion of PACAP38 Changes in regional cerebral blood flow (rCBF) in the area supplied by middle cerebral artery (MCA), blood flow in MCA, diameter of the superficial temporal artery (STA) and radial artery (RA)

Study Type

INTERVENTIONAL

Enrollment

Conditions

Migraine Without Aura

Interventions

PACAP38DRUG

10 pmol/kg/min given one time

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy migraine patient without aura * Aged 18-50 * 50-100 kg * Fertile women must use safe contraceptives (IUD, oral contraceptives, surgical sterilisation and long lasting gestagen. Exclusion Criteria: * Tension type headache more than five times/month * Other primary headaches * Daily medication except contraceptives * Drug taken within 4 times the halflife for the specific drug except contraceptives * Pregnant or lactating women * Exposure to radiation within the last year * Headache within the last 48 hours before start of trial * Hypertension * Hypotension * Respiratory or cardiac disease

Locations (1)

Dansih Headache Center

Glostrup Municipality, Denmark

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.